宫颈癌Foxm1蛋白表达与临床意义

Foxml protein expression in cervical cancer and its clinical significance

目的探讨Foxm1蛋白在宫颈癌发生和进展中的作用及其检测对宫颈癌的早期发现及恶性程度评估的意义。方法采集宫颈癌组织标本43例及正常子宫颈组织标本35例。采用免疫组化法检测标本中的Foxm1蛋白情况，分析宫颈癌组织Foxm1蛋白总体表达水平及细胞核中Foxm1蛋白表达与其病理特征的关系。结果宫颈癌组织Foxm1蛋白阳性表达率明显高于正常宫颈组织（P〈0．001）。宫颈癌组织的Foxm1蛋白表达评分明显高于正常宫颈组织（P〈0．001）。宫颈癌组织的不同病理类型、分化程度、FIGO分期、淋巴结转移间的Foxm1蛋白总表达评分比较差异无统计学意义（P〉0．05）。低分化、Ⅱ期、有淋巴结转移患者的肿瘤细胞核中的Foxm1蛋白表达水平明显高于高分化或中分化、0～Ⅰ期、无淋巴转移患者（P〈0．001）。结论Foxm1蛋白可能与宫颈癌的发生、进展相关，检测细胞核中的Foxm1蛋白的阳性表达水平可能利于在早期发现宫颈恶性病变及评估宫颈癌的恶性程度。

Objective To explore the role of Foxml in the occurrence and progression of cervical cancer and its significance in the early detection and severity evaluation of cervical cancer. Methods 43 specimens of cervical cancer tissue and 35 specimens of normal cervical tissue were collected. The Foxml protein expression situation in these sample was detected by immunohistochemical method, the relationship between the overall Foxml protein expression level, the nucleus Foxml protein expression level in cervical cancer tissue and pathological features were analyzed. Results The positive expression rate of Foxml protein in cervical cancer tissue was significantly higher than that in normal cervical tissue （P〈0.001）. The Foxml protein expression score in cervical cancer tissue was significantly higher than that in normal cervical tissue （P〈0.001）. The total Foxml protein expression scores among different pathological types, differentiated degree, FIGO stages, lymph node metastasis were not statistically significant （P〉0.05）. The tumor cell nucleus Foxml protein expression level in patients with low differentiation, Ⅱ stage, lymph node metastasis were significantly higher than those in patients with high or moderate differentiation, 0- Ⅰ stage, and patients without lymph node metastasis （P〈0.001）. Conclusion Foxml protein may be associated with the occurrence and progress of cervical cancer, detection of the nucleus Foxml protein positive expression level may be conducive to early finding cervical malignant lesions and evaluating severity of cervical cancer.